These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 37193456)
21. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries. Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146 [TBL] [Abstract][Full Text] [Related]
23. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines. García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212 [TBL] [Abstract][Full Text] [Related]
24. Two possible etiologies of Guillain-Barré syndrome: mRNA-1273 (Moderna) vaccination and scrub typhus: A case report. Hwang BW; Bong JB Medicine (Baltimore); 2022 Dec; 101(48):e32140. PubMed ID: 36482517 [TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. Baars AE; Kuitwaard K; de Koning LC; Luijten LWG; Kok WM; Eftimov F; Wieske L; Goedee HS; van der Pol WL; Blomkwist-Markens PH; Horemans AMC; Jacobs BC; van Doorn PA Neurology; 2023 Jan; 100(2):e182-e191. PubMed ID: 36127144 [TBL] [Abstract][Full Text] [Related]
26. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series. Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559 [TBL] [Abstract][Full Text] [Related]
27. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935 [TBL] [Abstract][Full Text] [Related]
28. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942 [TBL] [Abstract][Full Text] [Related]
29. Guillain-Barré syndrome in an era of global infections and 21st century vaccination. Lunn MP Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416 [TBL] [Abstract][Full Text] [Related]
30. COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism. Malekpour M; Khanmohammadi S; Meybodi MJE; Shekouh D; Rahmanian MR; Kardeh S; Azarpira N Immun Inflamm Dis; 2023 May; 11(5):e875. PubMed ID: 37249286 [TBL] [Abstract][Full Text] [Related]
31. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study. Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875 [TBL] [Abstract][Full Text] [Related]
32. Post coronavirus disease-2019 vaccination Guillain-Barré syndrome. Biswas A; Pandey SK; Kumar D; Vardhan H Indian J Public Health; 2021; 65(4):422-424. PubMed ID: 34975092 [TBL] [Abstract][Full Text] [Related]
33. A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barré Syndrome. Hilts A; Schreiber A; Singh A Am J Case Rep; 2022 Aug; 23():e936896. PubMed ID: 35945825 [TBL] [Abstract][Full Text] [Related]
34. Guillain-Barre syndrome and link with COVID-19 infection and vaccination: a review of literature. Valaparla VL; Rane SP; Patel C; Li X Front Neurol; 2024; 15():1396642. PubMed ID: 38899056 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome. Finsterer J; Matovu D; Scorza FA Clinics (Sao Paulo); 2022; 77():100064. PubMed ID: 35751951 [TBL] [Abstract][Full Text] [Related]
38. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Aladawi M; Elfil M; Abu-Esheh B; Abu Jazar D; Armouti A; Bayoumi A; Piccione E Can J Neurol Sci; 2022 Jan; 49(1):38-48. PubMed ID: 33949300 [TBL] [Abstract][Full Text] [Related]
39. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Abu-Rumeileh S; Abdelhak A; Foschi M; Tumani H; Otto M J Neurol; 2021 Apr; 268(4):1133-1170. PubMed ID: 32840686 [TBL] [Abstract][Full Text] [Related]
40. Temporal association between the age-specific incidence of Guillain-Barré syndrome and SARS-CoV-2 vaccination in Republic of Korea: a nationwide time-series correlation study. Lee H; Kwon D; Park S; Park SR; Chung D; Ha J Osong Public Health Res Perspect; 2023 Jun; 14(3):224-231. PubMed ID: 37415440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]